113-O16B

113-O16B is a synthetic ionizable lipid developed specifically for encapsulating messenger RNA in lipid nanoparticles, where it serves as the pivotal component that governs both nucleic acid loading efficiency and cytoplasmic release kinetics. Unlike early-generation cationic lipids that cause persistent membrane damage, 113-O16B features ester linkages that undergo rapid enzymatic cleavage in hepatocytes, so the lipid is degraded into innocuous metabolites once its delivery function is complete. Formulation scientists value 113-O16B for its compatibility with standard microfluidic mixing protocols: when combined with cholesterol, a helper phospholipid, and a PEGylated lipid, it yields homogeneous nanoparticles below 100 nanometers with encapsulation efficiencies routinely exceeding 90%. Preclinical programs spanning prophylactic vaccines, therapeutic cancer immunotherapy, and metabolic enzyme replacement have all adopted 113-O16B as the ionizable lipid backbone, confirming its broad utility across diverse mRNA cargoes and dosing schedules.

Product Parameters

Why Cosperpharm? – Our Competitive Advantages

Product Advantages

1. Esterase-triggered clearance reduces hepatic accumulation

The ester bonds built into 113-O16B are preferentially cleaved by carboxylesterases enriched in the liver, ensuring that the lipid is rapidly metabolized after mRNA delivery and does not accumulate over repeat administrations — a critical advantage for chronic dosing regimens.

2. Optimized pKa window for endosomal escape

The apparent pKa of 113-O16B falls within the 6.0–6.5 range, meaning the lipid acquires positive charge only as the endosome acidifies, minimizing off-target interactions in the bloodstream while maximizing fusion with the endosomal membrane and release of the mRNA payload.

3. Unsaturated tails promote non-bilayer phase formation

The cis double bonds in the hydrophobic domains of 113-O16B introduce kinks that destabilize lamellar lipid packing, lowering the energy barrier for the hexagonal-phase transition that is essential for efficient endosomal disruption and cytosolic delivery.

4. Ready-to-formulate liquid with excellent processability

113-O16B is supplied as a low-viscosity oil that dissolves rapidly in ethanol, enabling consistent microfluidic mixing with aqueous nucleic acid streams, smooth sterile filtration, and reproducible scale-up from bench to clinical manufacturing.

Contact us

Whether you are screening a library of ionizable lipids for a new mRNA indication or securing a commercial supply chain for a pivotal Phase 3 trial, Cosperpharm has the 113-O16B quality and scale you need. Reach out to our lipid team today — we will have a technical proposal and a transparent quote in your inbox within 48 hours.